Surrozen submits IND to FDA for DME therapeutic

Surrozen, Inc. has submitted an investigational new drug (IND) application to the FDA for SZN-8141, a bifunctional antibody targeting diabetic macular edema (DME) and wet age-related macular degeneration that activates Wnt signaling and inhibits VEGF. Preclinical studies demonstrate superior efficacy in reducing retinal vascular leakage and promoting vessel revascularization compared to existing therapies.

This Wire brief sits within Fusion42's coverage of Biotech.